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Background: Triptans, serotonin 5-HT1B/1D receptor agonists, exert their action by targeting serotonin 5-HT1B/1D
receptors, are used for treatment of migraine attack. Presently, 5 different triptans, namely sumatriptan, zolmitriptan,
eletriptan, rizatriptan, and naratriptan, are marketed in Japan. In the present study, we retrospectively analyzed the
relationships of clinical efficacy (headache relief) in Japanese and 5-HT1B/1D receptor occupancy (Φ1B and Φ1D).
Receptor occupancies were calculated from both the pharmacokinetic and pharmacodynamic data of triptans.
Methods: To evaluate the total amount of exposure to drug, we calculated the area under the plasma
concentration-time curve (AUCcp) and the areas under the time curves for Ф1B and Ф1D (AUCФ
1B and AUCФ
1D).
Moreover, parameters expressing drug transfer and binding rates (Acp, AФ
1B, AФ
1D) were calculated.
Results: Our calculations showed that Фmax
1B and Фmax
1D were relatively high at 32.0-89.4% and 68.4-96.2%,
respectively, suggesting that it is likely that a high occupancy is necessary to attain the clinical effect. In addition,
the relationships between therapeutic effect and AUCcp, AUCΦ
1B, AUCΦ
1D, and Acp・AUCcp differed with each





1D that was not affected by the drug and the form of administration.
Conclusions: These results suggest that receptor occupancy can be used as a parameter for a common index to
evaluate the therapeutic effect. We considered that the present findings provide useful information to support the
proper use of triptans.
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Triptans, serotonin 5-HT1B/1D receptor agonists, exert
their action by targeting serotonin 5-HT1B/1D receptors,
abundantly distributed in cerebral blood vessels, and are
used for treatment of migraine attack [1,2]. Presently, 5
different triptans, namely sumatriptan, zolmitriptan, ele-
triptan, rizatriptan, and naratriptan, are marketed in
Japan. Sumatriptan is available as injection, oral, and nasal
preparations, while zolmitriptan, eletriptan, rizatriptan,
and naratriptan are administered orally. However, dif-
ferences in their therapeutic effects among individuals and
drug characteristics, as well as lack of evidence for selec-
ting a suitable drug for each patient are problems to be
resolved [3]. For this reason, it is important to establish an* Correspondence: yamada@ps.toyaku.ac.jp
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in any medium, provided the original work is pindex for quantitative evaluation of the pharmacological
and clinical effects of triptans.
We have been studying the receptor occupancy, which
integrates pharmacokinetic and pharmacodynamics data,
of a variety of drugs that exert pharmacological effects
through receptors, and theoretically evaluated clinical
and adverse effects by retrospective analysis [4-7]. Our
findings for sumatriptan indicate that receptor binding
occupancy could be a useful parameter for clinical eva-
luation irrespective of the administered form [8]. In the
present study, we examined whether our analytical
method is applicable to all available triptans.Methods
We collected pharmacokinetic and pharmacodynamic pa-
rameters from administrations of sumatriptan (injectable,
oral and nasal preparations), zolmitriptan (oral pre-
paration), eletriptan (oral preparation), rizatriptan (oralan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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patients as well as available clinical efficacy data. In Japan,
substantial domestic clinical trial data are included in a
new medicine application data package. For the present
drugs identified as eligible for analysis, information regard-
ing approved indications, characteristics of the products,
and clinical trial data were extracted from review reports
downloaded from the website (http://www.info.pmda.go.jp)
of the regulatory authority (Pharmaceutical and Medical
Devices Agency, PMDA). When information was not pro-
vided on this website, we collected data from a relevant
published article.
Receptor occupancy following each administration was
calculated to investigate its relationship with clinical
effect.
Extraction of pharmacokinetic and pharmacodynamic
parameters
As pharmacokinetic parameters, changes in plasma drug
concentration following administration (Cp), maximum
plasma concentration (Cmax), time to maximum concen-
tration (Tmax), plasma unbound fraction value (fu), and
the presence of active metabolites were collected from
clinical trial data obtained from Japanese subjects. For
the pharmacodynamics parameters, the dissociation con-
stant (Ki) values of the serotonin 5-HT1B and 5-HT1D
receptors were collected.
Extraction of clinical trial data
To determine clinical effects, changes in values for head-
ache relief rate over time obtained in Phase II and III
clinical trials were collected.
Calculation of drug concentration and serotonin 5-HT1B/1D
receptor occupancy
Receptor occupancy [Ф (%)] for a particular drug was
calculated using (Eq. 1) when the target drug has no ac-
tive metabolite and only the unchanged drug was the ac-
tive form, where C is the drug concentration (nM) near
the receptor and Ki the dissociation constant (nM) from
each receptor [9].
Φ %ð Þ ¼ C
Cþ Ki  100 ð1Þ
When only one kind of active metabolite exists, occu-
pancy was calculated using (Eq. 2), where C1 and C2 are
the drug concentrations (nM) of the unchanged drug
near the receptor and active metabolite, respectively,
and Ki1 and Ki2 are the receptor dissociation constants
(nM) from each receptor of the unchanged drug and ac-
tive metabolite, respectively [9].Φ %ð Þ ¼ C1
C1 þ Ki1⋅ 1þ C2Ki2
 þ C2








If the unbound drug in plasma is speculated to simply
diffuse through the vascular wall to reach the intercellular
gap and reach instant equilibrium, the drug concentration
near the receptor, C, can be approximated based on the
plasma unbound drug concentration (Cf) obtained by
multiplying the plasma drug concentration (Cp) by the
plasma unbound fraction (fu): Cf = Cp x fu (nM). Fur-
thermore, by using the 5-HT1B and 5-HT1D receptor dis-
sociation constants (Ki
1B, Ki
1D), the occupancy for each
subtype, Ф1B and Ф1D, was calculated. On the basis of data
reported regarding the time course of plasma concentra-
tion after administration of each drug in Japanese subjects,
the plasma unbound drug concentration (Cf) was calcu-
lated. Then, Ф1B and Ф1D were calculated using Eq. 1 or
Eq. 2 to examine changes over time.
Calculation of total amount of exposure to drug and
serotonin 5-HT1B/1D receptor occupancy
The area under the plasma concentration-time curve
(AUCcp) and the areas under the time curves for Ф1B
and Ф1D (AUCФ
1B and AUCФ
1D) from the start of drug
administration to the time of evaluating headache relief
[t (hr)] were calculated using the trapezoidal method.
Calculation of systemic drug transfer and serotonin
5-HT1B/1D receptor binding rates
It has been suggested that the onset of the effect of trip-
tans is related to the systemic drug-transfer rate [10], thus
parameters expressing drug transfer and binding rates
(Acp, AФ
1B, AФ
1D) were calculated by using (Eq. 3, 4, 5),
where the maximum plasma concentration was Cmax, and
the time to maximum concentration Tmax and the maxi-
mum occupancy were Фmax
1B and Фmax
1D, respectively.
Acp ¼ Cmax=Tmax ð3Þ
AΦ
1B ¼ Φmax1B=Tmax ð4Þ
AΦ
1D ¼ Φmax1D=Tmax ð5Þ
Analysis of relationship between parameters for receptor
occupancy and clinical effects of each drug following
administration
The relationship of each parameter, obtained as noted in
Section 2, with clinical effects was examined. We initially in-
vestigated the relationship of AUCcp, AUCФ
1B, and AUCФ
1D






Table 2 Time courses for headache relief (percent of patients (%)) in Japanese subjects [11,16,21-27]
t (Time after administration) (hr) 0.17 0.25 0.5 0.75 1 1.5 2 3 4
Sumatriptan [11,21,22]
SC 3 mg※ 30.3 37.0-63.3 62.0-81.8 73.7 78.9-93.9 - - - -
SC 6 mg - 71.4 71.4 - 85.7 - - - -
Sumatriptan [23]
PO 50 mg※ - - 7 - 32 - 41 63 68
PO 100 mg - - 10 - 29 - 55 65 68
Sumatriptan [24]
NS 10 mg - - 19.3 - 33.3 - 58.9 - 62.5
NS 20 mg※ - - 15.7-27.8 - 31.5-56.4 49.1 63.0-70.9 - 73.2
Zolmitriptan [16]
PO 2.5 mg※ - - 9.8 - 28.3 - 55.6 - 76.5
Eletriptan [25]
PO 20 mg※ - - 13 - 37 - 64 - 86
PO 40 mg - - 12 - 33 - 67 - 88
Rizatriptan [26]
PO 10 mg※ - - 10.1 - 26.1 50.7 59.4 - -
Naratriptan [27]
PO 1 mg - - - - 21.2 - 41.3 60.6 71.2
PO 2.5 mg※ - - - - 15.6 - 50.5 71.6 77.1









MW (g/mol) Plasma unbound
fraction; fu
Ki1B* (nM) Ki1D* (nM)
Sumatriptan [11-13] SC 3 295.41 0.66 12.6 12.6
PO 50
NS 20
Zolmitriptan [14-16] PO 2.5 [unchanged drug] [unchanged drug] [unchanged drug] [unchanged drug]
ODT 287.30 0.8 6.31 2.51
[active metabolite] [active metabolite] [active metabolite] [active metabolite]
273.36 0.75 1.58 0.5
Eletriptan [17] PO 20 382.52 0.13 10.0 1.2
Rizatriptan [18,19] PO 10 269.35 0.86 138 13.1
ODT
Naratriptan [20] PO 2.5 335.47 0.71 2.2 2.3




ODT: orally disintegrating tablet.
Ki1B: 5-HT1B receptor dissociation constant.
Ki1D: 5-HT1D receptor dissociation constant.
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by Acp, AФ
1B, and AФ
1D obtained with the equations, Eq. 3,
Eq. 4, and Eq. 5, and coupled with the rate were calculated
for evaluating the relationship with headache relief rate.
When an association was found between a parameter and
headache relief rate, analysis was conducted by using the
sigmoid Emax model shown in Eq. 6, where E is headache
relief rate (%), Emax the maximum headache relief rate (%),
X the parameters with a favorable relationship with head-
ache relief rate, EC50 the value of X when Emax was 50%,
and γ the Hill coefficient. The relationship between X and
headache relief rate (E) was analyzed using a nonlinear least
squares method to calculate Emax, EC50, and γ. For the ana-
lyses, we used the MLAB software package (Civilized
Software Inc.).Figure 1 Time courses of Ф1B and Ф1D of the tested triptans in varyin
solid line: standard dose in Japan).E ¼ Emax・Xγ= EC50 þ Xγð Þ ð6Þ
Results
Extraction of pharmacokinetic and pharmacodynamic
parameters
The various parameters collected for each drug are
shown in Table 1.
For pharmacodynamic parameters, the value of Ki was
calculated on the basis of the reported values for pKi and
pIC50 of the 5-HT1B and 5-HT1D receptors. Sumatriptan
and naratriptan showed nearly the same levels for those
receptors, while zolmitriptan (unchanged drug and active
metabolite), eletriptan, and rizatriptan tended to show a
higher affinity for 5-HT1D than 5-HT1B.g doses. (SC: subcutaneous injection, PO: oral tablet, NS: nasal spray,
Table 3 Calculated (1) AUCcp, (2) AUCΦ
1B, and (3) AUCΦ
1D values
t (Time after administration) (hr) 0.17 0.25 0.5 0.75 1 1.5 2 3 4
(1) AUCcp (ng・hr/mL)
Sumatriptan
SC 3 mg※ 4.9 8.3 17.0 22.6 26.4 - - - -
SC 6 mg - 17.0 34.8 - 51.9 - - - -
Sumatriptan
PO 50 mg※ - - 4.7 - 15.7 - 40.0 66.4 87.4
PO 100 mg - - 9.7 - 32.6 - 83.3 138.6 181.6
Sumatriptan
NS 10 mg - - 1.2 - 4.0 - 10.7 - 18.2
NS 20 mg※ - - 3.5 - 7.2 12.8 19.4 - 38.0
Zolmitriptan
PO 2.5 mg※ - - 0.51 - 1.87 - 5.4 - 11.3
Eletriptan
PO 20 mg※ - - 7.7 - 25.2 - 56.9 - 99.2
PO 40 mg - - 12.4 - 43.0 - 105.9 - 214.1
Rizatriptan
PO 10 mg※ - - 3.6 - 11.8 20.6 28.5 - -
Naratriptan
PO 1 mg - - - - 0.8 - 2.7 4.6 6.4




SC 3 mg※ 11.3 18.3 39.7 59.6 77.7 - - - -
SC 6 mg - 19.6 42.7 - 85.0 - - - -
Sumatriptan
PO 50 mg※ - - 19.3 - 58.9 - 140.0 222.5 300.4
PO 100 mg - - 21.8 - 66.3 - 156.2 247.0 334.9
Sumatriptan
NS 10 mg - - 14.5 - 38.9 - 93.2 - 169.2
NS 20 mg※ - - 26.3 - 54.6 87.5 122.6 - 243.2
Zolmitriptan
PO 2.5 mg※ - - 17.1 - 55.2 - 140.7 - 314.9
Eletriptan
PO 20 mg※ - - 12.5 - 38.6 - 87.3 - 163.2
PO 40 mg - - 15.3 - 47.9 - 113.3 - 237.2
Rizatriptan
PO 10 mg※ - - 6.2 - 19.9 34.4 47.8 - -
Naratriptan
PO 1 mg - - - - 36.9 - 101.2 165.7 229.1




SC 3 mg※ 11.3 18.3 39.7 59.6 77.7 - - - -
SC 6 mg - 19.6 42.7 - 85.0 - - - -
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Table 3 Calculated (1) AUCcp, (2) AUCΦ
1B, and (3) AUCΦ
1D values (Continued)
Sumatriptan
PO 50 mg※ - - 19.3 - 58.9 - 140.0 222.5 300.4
PO 100 mg - - 21.8 - 66.3 - 156.2 247.0 334.9
Sumatriptan
NS 10 mg - - 14.5 - 38.9 - 93.2 - 169.2
NS 20 mg※ - - 26.3 - 54.6 87.5 122.6 - 243.2
Zolmitriptan
PO 2.5 mg※ - - 21.6 - 66.6 - 161.2 - 351.8
Eletriptan
PO 20 mg※ - - 22.3 - 67.4 - 156.0 - 322.9
PO 40 mg - - 23.2 - 70.2 - 164.2 - 350.5
Rizatriptan
PO 10 mg※ - - 19.4 - 59.3 99.8 139.5 - -
Naratriptan
PO 1 mg - - - - 36.9 - 101.2 165.7 229.1
PO 2.5 mg※ - - - - 53.9 - 135.1 216.7 297.6
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Table 2 shows reported time courses for headache relief
rate in Japanese subjects given each drug at various
doses in clinical trial settings.
The sumatriptan injectable preparation showed a high
level of headache relief from the initial stage of adminis-
tration, with 60% or greater at 0.5 hours and 80% or more
at 1 hour after administration. Moreover, the sumatriptan
nasal preparation tended to exert its effect earlier than the
other drugs. However, a relief rate of about 60-88% was
attained from 2 hours with these drugs and preparations.
Calculation of serotonin 5-HT1B/1D receptor occupancy at
time of administration of each drug
The time courses of Ф1B and Ф1D calculated on the basis
of changes in plasma concentration after administration
of the tested triptans in varying doses [11,16,23-27]
demonstrated different aspects depending on the drug
and dosage form (Figure 1).
Sumatriptan and naratriptan showed nearly the same
transition for the 5-HT1B and 5-HT1D receptors, while
zolmitriptan, eletriptan, and rizatriptan showed higher Ф
values for the 5HT1D receptor than the 5-HT1B receptor.
Calculation of total amount of exposure to drug and
serotonin 5-HT1B/1D receptor occupancy
Table 3 shows the AUCcp, AUCФ
1B, and AUCФ
1D values
from the time of administration until each evaluation
time when headache relief rate was determined by the
trapezoidal method.Calculation of systemic drug-transfer rate and rate of
serotonin 5-HT1B/1D receptor binding
Table 4 shows calculated values for Tmax, Cmax, the ab-
sorption rate-related parameters Acp (Cmax/Tmax), Фmax
1B,
Фmax






For Tmax, the sumatriptan injectable preparation was
the fastest at about 0.2 hours, followed by the nasal
preparation at about 1 hour and the tablet at about 1-3
hours. As for Ф, Фmax
1B at the standard dose of each
drug ranged from 32.0-89.4%, while Фmax
1D ranged from
68.4-96.2%.Analyses of relationships between parameters for
receptor occupancy and clinical effects at the time of
administration of each drug
We examined the relationships between the parameters
obtained as noted in Section 2 above and clinical effects.
As for that between AUCcp and headache relief rate, re-
lief rate increased along with AUCcp increases. However,
that relationship tended to vary among the tested drugs
(Figure 2).
For the relationship of AUCФ
1B and AUCФ
1D with head-
ache relief rate, the elevation of both was related to in-
creased headache relief rate, with different tendencies
depending on the drug. We also found that a relationship
with 5-HT1D receptors was likely for the oral preparations
irrespective of drug, while the injectable and nasal prepa-
rations showed different aspects (Figure 3).




















SC 3 mg※ 0.21 44 209.52 88.6 88.6 422.09 422.09
SC 6 mg 0.2 95.5 477.50 94.4 94.4 472.12 472.12
Sumatriptan [23]
PO 50 mg※ 1.8 32.6 18.11 85.3 85.3 47.36 47.36
PO 100 mg 2 58.2 29.10 91.2 91.2 45.58 45.58
Sumatriptan [24]
NS 10 mg 1.1 6.4 5.82 53.2 53.2 48.33 48.33
NS 20 mg※ 1.3 12.2 9.38 68.4 68.4 52.61 52.61
Zolmitriptan [16]
PO 2.5 mg※ [unchanged drug] [unchanged drug] [unchanged drug] 89.4 96.2 26.79 32.1
3 5.23 1.74
[active metabolite] [active metabolite] [active metabolite]
3 3.5 1.17
Eletriptan [25]
PO 20 mg※ 1 38.9 38.90 56.9 91.7 56.93 91.7
PO 40 mg 1.2 69.7 58.08 70.3 95.2 58.6 79.3
Rizatriptan [26]
PO 10 mg※ 1 20.3 20.30 32.0 83.2 32.0 83.2
Naratriptan [27]
PO 1 mg 2.17 2.12 0.98 67.1 66.1 30.9 30.5
PO 2.5 mg※ 2.68 5.62 2.10 84.4 83.8 31.5 31.3




Tmax: time to Cmax.





Figure 2 Relationship between AUCcp and headache relief rate.
(SC: subcutaneous injection, PO: oral tablet, NS: nasal spray).
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(Acp・AUCcp), in which the value for plasma drug
concentration-related Acp was coupled with velocity,
and headache relief rate.
In the analysis using Acp・AUCcp, headache relief rate
was increased along with the increase in Acp・AUCcp.
However, the relationship varied depending on the drug.





1D), in which receptor
occupancy-related AФ was coupled with velocity, was
likely to be assimilated into a single line.
As a result of our analysis using the sigmoid Emax
model, the fitted curve of our model corresponded well
to the actual measurement value (Figure 5). The corre-
lation coefficient was 0.90 for the 5-HT1B receptor and
0.92 for the 5-HT1D receptor. The parameters obtained
are shown in Table 5.
Figure 3 Relationships between AUCΦ
1B or AUCΦ
1D and headache relief rate. (SC: subcutaneous injection, PO: oral tablet, NS: nasal spray).






assimilated into a single line irrespective of drug kind
and dosage form, though the correlation was higher for
the 5-HT1D receptor than the 5-HT1B receptor.
Discussion
In our previous study, as an attempt to establish in-
formation for the optimal use of triptans, we focused on
sumatriptan, which has multiple drug formulations
available [8]. Our results clarified that the parameter
AФ・AUCФ, in which the receptor binding occupancy of
the action target, the 5-HT1B/1D receptor, and occupancy
rate were taken into account, was a good index for
quantitatively evaluating clinical efficacy without regard
to dosage form. In the present study, for the purpose of
evaluating whether our method is applicable for analysis
of triptans in general, we examined values obtained
when various triptan preparations were administered to
Japanese subjects.
In principle, the pharmacokinetic data were collected
from clinical trial data obtained from Japanese subjects.Figure 4 Relationship between ACP・AUCCP and headache relief
rate. (SC: subcutaneous injection, PO: oral tablet, NS: nasal spray).For zolmitriptan, the presence of an active metabolite,
which contributes to drug efficacy, was taken into ac-
count in the analysis. Moreover, for eletriptan and riza-
triptan, the presence of an active metabolite was not
taken into account, as its contribution to efficacy is re-
ported to be low.
For the pharmacodynamic data, the value of Ki, which
represents affinity for the 5-HT1B and 5-HT1D receptors,
was investigated. Generally, it is desirable to use data mea-
sured simultaneously in identical experimental systems.
However, since no such data were available, we used
values previously reported for each drug. More precise
analysis might be achieved in the future if Ki values mea-
sured under the same condition could be obtained. The Ki
values varied among the drugs. Also, the degree of affinity
for the 5-HT1B and 5-HT1D receptors was found to vary
depending on the drug.
For the present analysis, the drug concentration near
the target receptors was considered to be at the same
level as that of the unbound drug in plasma. It was pre-
viously reported that the 5-HT1B receptor, an action tar-
get of triptans, is present in the intra-cranial vessels,
while the 5-HT1D receptor exists in the trigeminal nerve
around the intra-cranial vessels [28]. However, there are
no known reports of direct measurements of drug con-
centration near these receptors. Accordingly, we spe-
culated that a drug unbound from plasma protein may
reach the action site by permeation through the vessel wall
after being transferred to blood following administration.
The blood-brain barrier (BBB) penetration of triptan
differs in each drug. Sumatriptan and naratriptan espe-
cially are scarcely passing through BBB and showing a
thin distribution in the central nervous system [20,29].
However, they elicited the same therapeutic effect for
migraine as other triptans. Furthermore, Tomita et al.
suggested that triptans also acted on 5-HT1B/1D recep-
tors in the trigeminal and dorsal root ganglion cells
where BBB was lacked rather than in the sites with BBB




1D and headache relief rate. (SC: subcutaneous injection, PO: oral tablet,
NS: nasal spray, Solid line: Fitting curve).
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this study, we have taken into account only vascular
permeability of triptans. In future, the target tissue and
receptor of triptans become clearer. And if actual mea-
surement drug concentration at the target site is ob-
tained, we will be able to do more accurate analysis in
consideration of BBB penetration.
Using the collected data, changes in receptor occu-
pancy, shown by Ф1B and Ф1D, were calculated on the
basis of reported changes in plasma drug concentration.
As shown in Figure 1, sumatriptan and naratriptan
had nearly the same changes for both the 5-HT1B and
5-HT1D receptors, as our results revealed nearly the
same Ki values for those receptors. Meanwhile, zolmitri-
tan, eletriptan, and rizatriptan demonstrated changes
when Ф was higher for the 5-HT1D receptor than for the
5-HT1B receptor, as the affinity for the 5-HT1D receptor
was greater.
Using reported Cmax values, we calculated Фmax
1B and
Фmax
1D. As shown in Table 4, the Cmax values varied
greatly depending on the drug. Meanwhile, as a certain ef-
fect was obtained without regard to the kind and dosage
form, it was considered difficult to quantitatively predict
the clinical effect on the basis of the plasma drug concen-
tration. Our calculations showed that Фmax
1B and Фmax
1D
were relatively high at 32.0-89.4% and 68.4-96.2%, respec-
tively, suggesting that it is likely that a high occupancy is
necessary to attain the clinical effect. Sumatriptan showedTable 5 Estimated value of Emax, EC50, and γ






Emax 92.5 ± 9.9 92.5 ± 8.5
EC50 3529.7 ± 985.6 4740.0 ± 995.7
γ 0.97 ± 0.18 1.11 ± 0.18a greater than 3.6-fold difference for Cmax between the in-
jectable (3 mg) and nasal (20 mg) preparations at the usual
dose. However, the difference between Фmax
1B and Фmax
1D
was about 1.3-fold, which was not as great as that seen in
regard to blood concentration. On the basis of these
findings, we considered that Ф could be quantitatively
indicative of the clinical effect, which was difficult to
evaluate by using plasma drug concentration. Further-
more, the value for Ф necessary for the onset of efficacy
could be attained in all of the dosage forms. Thus, it is
suggested that Ф might be useful for quantitative eva-
luation of the clinical efficacy of each dosage form.
We have reported many papers about the relationships
between the receptor binding occupancies and clinical
effects or adverse reactions in the various kinds of drugs.
Among these articles, for benzodiazepines, dopamine D2
antagonists, dopamine D2 agonists, and histamine H1
antagonists, we reported that theoretical calculated va-
lues reflected the actual values measured by Positron
Emission Tomography (PET) [10,31-34]. Also, with re-
gard to other drugs, we suggested that it was possible to
analyze the effects of drugs by using theoretical calcu-
lated values [4-7,35].
We also examined the relationship between clinical ef-
fect and Ф. Data for the time course of clinical effect were
mainly extracted from the results of Phase II and III clin-
ical trials performed in Japan. Meanwhile, in pharmacoki-
netic data mainly obtained in Phase I trials of healthy
adults, bioequivalence was shown to be obtained between
healthy adults and patients with migraine when a tablet
preparation was used [36]. Accordingly, in the present
study we used data for our analyses based on the specula-
tion that they were the same as those obtained when tab-
lets were given to patients. In clinical trials of migraine
therapeutic agents, headache relief rate at 2 hours after
administration is typically used as a major evaluation time
point. In the present study, with the time factor taken into
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ondary end point.
In our analysis of the relationship with headache relief
rate, a different profile was suggested between drug kind
or dosage form for AUCcp, AUCФ
1B, and AUCФ
1D, which
showed no definite relationship. For the parameter
Acp・AUCcp, in which velocity was taken into conside-
ration, differences were observed among the prepara-





1D, for receptor occupancy coupled with
velocity, a relationship was observed irrespective of drug
kind and dosage form, which could be assimilated into a
single line. Moreover, the 5-HT1D receptor showed a
better correlation coefficient than the 5-HT1B receptor.
It was previously reported that the contribution to
clinical efficacy varied between the 5-HT1B and 5-HT1D
receptors [37]. Our findings suggest that the 5-HT1D re-
ceptor has a greater contribution, though additional
study is necessary.
Our findings indicate that is difficult to evaluate the
relationship of triptan preparations with clinical efficacy
by using only plasma drug concentration. However, that
could be evaluated by using receptor occupancy. Fur-
thermore, clinical efficacy might be determined with
higher precision by taking into account the rate of re-
ceptor binding. Thus, we considered that the parameter
AФ
1D・AUCФ
1D is a useful index for evaluating clinical
effect.
It is likely that the clinical efficacy of triptans can not
be accurately evaluated by using plasma drug concentra-
tion, if a drug such as zolmitriptan with an active me-
tabolite is analyzed only based on the unchanged drug
concentration. In light of this, evaluation on the basis of
receptor occupancy, which can quantify by taking into
consideration the presence of the active metabolite, is
considered appropriate.
A previous report [10] suggested that absorption rate
should be taken into consideration when examining the
clinical efficacy of sumatriptan and the present results
support those findings. Moreover, to set a parameter that
takes into consideration absorption rate, a prior study
[38] investigated that of sumatriptan at the time of initial
administration by using Cmax/Tmax. The values reported
in that study were similar to our results. Accordingly, it
is considered that our method for taking into consi-
deration velocity might be appropriate.Conclusions
We suggest a common index that enables evaluation of
the clinical efficacy of triptans irrespective of drug kind
and dosage form by using a single line. We concluded
that the preparation choice and prediction of clinical ef-
fect of an additional dose for appropriately designing anadministration plan can be realized by use of a standard
curve. Thus, by calculating AФ and AUCФ for attaining
the full clinical effect, changes in plasma drug concen-
tration can be obtained, making possible an estimation
based on drug, dosage form, and dose. Receptor occu-
pancy can be used as a parameter for a common index
to evaluate the therapeutic effect. We considered that
the present findings provide useful information to sup-
port the proper use of triptans. In a future study, we in-
tend to develop a system for clinical application.
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